Case Reports

Guttate Psoriasis Following COVID-19 Infection

Author and Disclosure Information

 

References

Conclusion

Psoriasis, a chronic inflammatory skin condition, has been linked predominantly to genetic and environmental factors. Guttate psoriasis as a secondary reaction after streptococcal tonsillar and respiratory infections has been reported.1

Our case is the fourth documented case of guttate psoriasis secondary to COVID-19 infection.2-4 However, it is the second documented case of a patient with a diagnosis of guttate psoriasis secondary to COVID-19 infection who had neither a personal nor family history of psoriasis.

Because SARS-CoV-2 is a novel virus, the long-term effects of COVID-19 remain unclear. We report this case and its findings to introduce a novel clinical manifestation of SARS-CoV-2 infection.

Pages

Recommended Reading

COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
Covid ICYMI
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
Covid ICYMI
Biologics may protect psoriasis patients against severe COVID-19
Covid ICYMI
COVID-19 vaccines: Safe for immunocompromised patients?
Covid ICYMI
Pandemic puts patients with psoriatic disease off seeking medical help
Covid ICYMI
National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine
Covid ICYMI
Researchers stress importance of second COVID-19 vaccine dose for infliximab users
Covid ICYMI
Psoriasis associated with an increased risk of COVID-19 in real-world study
Covid ICYMI
Patients on methotrexate show T-cell response to Pfizer vaccine
Covid ICYMI
Better COVID-19 outcomes confirmed in TNF inhibitor users
Covid ICYMI